Neuroglee
Neuroglee offers personalised digital therapeutics and virtual care solutions for neurodegenerative diseases.
Neuroglee offers personalised digital therapeutics and virtual care solutions for neurodegenerative diseases.
IDS Medical Group (idsMED) leading integrated solutions provider of medical equipment, supplies, and services in Asia with a presence in six markets.
Genesis MedTech Group is a Singapore-based medical device company that offers multi-therapy products for emerging markets. It has a global platform that covers research, production, quality, supply, marketing, and sales of its products. It has a team of professionals and entrepreneurs with MedTech experience worldwide and in Asia.
Resolve Biosciences empowers scientists with Molecular Cartography™ to gain new insights into spatial biology and advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, infectious disease, and agriculture.
Resolve Biosciences Read More »
ImmunoScape is a pre-clinical biotechnology company developing next-generation TCR cell therapies for cancer.
RVAC Medicines is a mRNA biopharmaceutical company that develops innovative mRNA vaccines and therapeutics for unmet medical needs.
Aspen Neuroscience combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments.
Aspen Neuroscience Read More »
A technology-driven company that empowers transformative cell and gene therapies through an integrated technologies model, combining R&D platforms and process development for discovery and development of advanced therapeutics.
Now known as Standard BioTools Inc, Fluidigm’s technologies and products based on microfluidics and mass cytometry enable the exploration and analysis of individual cells, as well as the industrial application of genomics. Listed on NASDAQ in 2011.
A large-scale cell culture manufacturing site for the production of monoclonal antibodies and recombinant proteins. Acquired by Lonza Group in 2008.